R403
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 2
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- E2F_TARGETS+0.350
- SPERMATOGENESIS+0.340
- G2M_CHECKPOINT+0.330
- APICAL_SURFACE+0.300
- KRAS_SIGNALING_DN+0.230
- ESTROGEN_RESPONSE_LATE+0.200
- APICAL_JUNCTION+0.160
- ANGIOGENESIS+0.150
- COAGULATION+0.150
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.430
- PROTEIN_SECRETION-0.350
- PI3K_AKT_MTOR_SIGNALING-0.340
- UNFOLDED_PROTEIN_RESPONSE-0.340
- MTORC1_SIGNALING-0.300
- INTERFERON_ALPHA_RESPONSE-0.280
- IL6_JAK_STAT3_SIGNALING-0.260
- INTERFERON_GAMMA_RESPONSE-0.260
- P53_PATHWAY-0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0317 | Med | Medulloblastoma | 0.822 |
| 2 | SRR1516036 | — | — | 0.811 |
| 3 | 82982 | EPN | Supratentorial EPN | 0.800 |
| 4 | MDT-AP-3175 | Med | Medulloblastoma | 0.798 |
| 5 | SRR12202490 | — | — | 0.792 |
| 6 | SRR1797259 | — | cohortSC | 0.780 |
| 7 | MNG35 | — | — | 0.767 |
| 8 | SRR1516070 | — | — | 0.764 |
| 9 | MDT-AP-0374 | Med | Medulloblastoma | 0.762 |
| 10 | MNG472 | — | — | 0.753 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.340 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| MYOGENESIS | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.010 | Inavolisib | — uncovered |